Your Search Results

Bailout techniques for complications during primary PCI

21 May 2026 – From EuroPCR 2026

This session addresses bailout techniques during primary PCI complications. It covers a range of challenging scenarios such as coronary perforations and complex procedural issues, emphasizing rapid decision-making and effective treatment strategies to improve patient outcomes in high-stakes situations.

CTO ADVANCED Level III: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland

21 May 2026 – From EuroPCR 2026

This advanced educational session features live complex chronic total occlusion (CTO) PCI cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel. It emphasizes optimizing strategy selection, procedural efficiency across diverse CTO anatomies, and integrating advanced techniques into routine complex practice.

Beyond the diagnosis: a qualitative exploration of women’s experiences with cardiovascular disease

21 May 2026 – From EuroPCR 2026

This session presents a qualitative exploration of women's experiences with cardiovascular disease, highlighting unique challenges throughout their care pathway from diagnosis to rehabilitation. It shares robust patient experience data and offers recommendations aimed at improving cardiovascular care tailored to women’s specific needs.

Beyond first implant: valve-in-valve, redo and leaflet modification

20 May 2026 – From EuroPCR 2026

This session explores advanced transcatheter aortic valve therapies beyond the first implant, focusing on valve-in-valve, redo procedures, and leaflet modification techniques. Topics include bioprosthetic valve fracture, long-term outcomes from the DURA-ViV registry, simplified workflows for leaflet modification in redo-TAVI, and intravascular ultrasound evaluation of valve expansion...

The impact of calcified and resistant lesions in clinical outcome of PCI

21 May 2026 – From EuroPCR 2026

Delve into the clinical implications of calcified and resistant coronary lesions on percutaneous coronary intervention (PCI) outcomes. This session presents key registry data and study results on intravascular lithotripsy and plaque modification techniques, highlighting their impact on patient prognosis and stent performance.

New evidence for pharmacology for coronary artery disease

19 May 2026 – From EuroPCR 2026

This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...

Best complications on calcified lesions

20 May 2026 – From EuroPCR 2026

Highlighting challenging cases in calcified coronary lesions, this session presents a series of complications including stuck wires, the Kokeshi phenomenon, and multiple complications within a single vessel. It provides practical insights into rescue techniques and navigating complex procedural challenges.

TAVI complications - Prediction, reduction, avoidance

21 May 2026 – From EuroPCR 2026

This session examines prediction, reduction, and avoidance of complications associated with TAVI procedures. It covers outcomes of second-valve implantation as a bail-out for valve migration, predictors of permanent pacemaker implantation post-TAVI from the LANDMARK trial, neurological event prognostics based on timing, and management of periprocedural cardiac...

Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial

29 Mar 2025

Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.

Author

Ali Nazmi Calik

$Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial$

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

18 May 2021

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial

Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials

14 Nov 2021

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.